UNCONVENTIONAL FRACTIONATION RADIOTHERAPY REGIMENS IN TREATMENT OF INOPERABLE LUNG CANCER
-
Published:2019-09-01
Issue:4
Volume:18
Page:21-26
-
ISSN:2312-3168
-
Container-title:Siberian journal of oncology
-
language:
-
Short-container-title:Sib. onkol. ž.
Author:
Gogolin D. V.1, Gulidov I. A.1, Medvedeva K. E.1, Ragulin Y. A.1, Mardinsky Y. S.1, Ivanova I. N.1, Kursova L. V.1, Kotuhov I. I.1, Buksha A. Y.1
Affiliation:
1. A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological
Center of the Ministry of Health of the Russian Federation
Abstract
The purpose of the study was to compare the efficacy and toxicity of hypofractionated versus hyperfractionated radiotherapy in patients with inoperable lung cancer.Material and Methods. Patients with inoperable lung cancer, who were treated between 2014 and 2017, were assigned to undergo radiotherapy in two arms: accelerated hypofractionated conformal radiotherapy arm with 70 patients (60 Gy in 25 fractions, with 2.4 Gy per fraction) and accelerated hyperfractionated radiotherapy with 49 patients (60–70 Gy with 1–1.5 Gy per fraction). At the same time, platinum-based chemotherapy was applied.Results. The rates of partial response, complete response, stable disease and progressive disease were 44.3, 7.2, 38.5 and 10.0 %, respectively in patients with hypofractionated conformal radiotherapy arm. The corresponding values were 71.4, 6.1, 16.4 and 6.1 %, respectively in patients with hyperfractionated radiotherapy arm. The 2-year overall survival rate was 62.8 % for the hypofractionated group and 58.1 % for the hyperfractionated group. Esophagitis III grade was observed in 4 (5.7 %) patients of the hypofractionated group and in 3 (6.5 %) patients of the hypofractionated group. Pneumonitis III grade was reported in 2 (2.9 %) patients in the hypofractionated radiotherapy arm and in 4 (8.7 %) patients in the hyperfractionated radiotherapy arm.Conclusion. Results of the study showed that 3D-conformal hypofractionated radiotherapy combined with concurrent chemotherapy resulted no in severe radiation-induced complications, and demonstrated satisfactory short-and long-term treatment outcomes.
Publisher
Tomsk Cancer Research Institute
Subject
Cancer Research,Oncology
Reference10 articles.
1. Trakhtenberg A.Kh., Frank G.A., Kolbanov K.I., Sedykh S.A., Pikin O.V. Lung tumors. Oncology manual. Moscow, 2008. 326. (in Russian). 2. Kaprin A.D., Starinskii V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow, 2017. 250. (in Russian). 3. Ramroth J., Cutter D.J., Darby S.C., Higgins G.S., McGale P., Partridge M., Taylor C.W. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4): 736–747. doi: 10.1016/j.ijrobp.2016.07.022. 4. O’Rourke N., Roqué I., Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010 Jun 16; (6): CD002140. doi: 10.1002/14651858. CD002140.pub3. 5. Rodrigues G., Choy H., Bradley J., Rosenzweig K.E., Bogart J., Curran W.J.Jr., Gore E., Langer C., Louie A.V., Lutz S., Machtay M., Puri V., Werner-Wasik M., Videtic G.M. Definitive radiotherapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015 May-Jun; 5(3): 141–8. doi: 10.1016/j. prro.2015.02.012.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|